论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Huang H, Liao D, Pu R, Cui Y
Received 29 August 2018
Accepted for publication 28 September 2018
Published 14 November 2018 Volume 2018:11 Pages 729—742
DOI https://doi.org/10.2147/DMSO.S185672
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Konstantinos Tziomalos
Purpose: Spirulina
is generally used as a nutraceutical food supplement due to its nutrient
profile, lack of toxicity, and therapeutic effects. Clinical trials have
investigated the influence of spirulina on metabolic-related risk factors but
have yielded conflicting results in humans. Here, we summarize the evidence of
the effects of spirulina on serum lipid profile, glucose management, BP, and
body weight by conducting a meta-analysis.
Materials and methods: Relevant
studies were retrieved by systematic search of MEDLINE, EMBASE, Scopus
databases, and reference lists of relevant original studies from inception to
July 2018. Data were extracted following a standardized protocol. Two
investigators independently extracted study characteristics, outcomes measures,
and appraised methodological quality. Effect sizes were performed using a
random-effects model, with weighted mean differences (WMDs) and 95% CIs between
the means for the spirulina intervention and control arms. Subgroup analyses
were conducted to explore the possible influences of study characteristics.
Publication bias and sensitivity analysis were also performed.
Results: A total
of 1,868 records were identified of which 12 trials with 14 arms were eligible.
The amount of spirulina ranged from 1 to 19 g/d, and intervention durations
ranged from 2 to 48 weeks. Overall, data synthesis showed that spirulina
supplements significantly lowered total cholesterol (WMD = –36.60 mg/dL; 95%
CI: −51.87 to –21.33; P =0.0001), low-density lipoprotein cholesterol (WMD =
–33.16 mg/dL; 95% CI: −50.52 to –15.75; P =0.0002), triglycerides (WMD = –39.20 mg/dL; 95% CI:
−52.71 to –25.69; P =0.0001), very-low-density lipoprotein cholesterol
(WMD = –8.02 mg/dL; 95% CI: −8.77 to –7.26; P =0.0001), fasting
blood glucose (WMD = –5.01 mg/dL; 95% CI: −9.78 to –0.24; P =0.04), and DBP
(WMD = –7.17 mmHg; 95% CI: −8.57 to –5.78; P =0.001). These
findings remained stable in the sensitivity analysis, and no obvious
publication bias was detected.
Conclusion: Our
findings provide substantial evidence that spirulina supplementation has
favorable effect on select cardiovascular and metabolic biomarkers in humans,
including lipid, glucose, and DBP management.
Keywords: blood
pressure, body weight, blood glucose, CVD, lipid, spirulina